160
Participants
Start Date
December 31, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
November 30, 2013
Placebo MDPI
Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Albuterol MDPI
Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Teva Investigational Site 10225, Costa Mesa
Teva Investigational Site 10250, Encinitas
Teva Investigational Site 10230, Huntington Beach
Teva Investigational Site 10255, Palmdale
Teva Investigational Site 10231, Rancho Mirage
Teva Investigational Site 10252, Riverside
Teva Investigational Site 10242, Rolling Hills Estates
Teva Investigational Site 10238, San Diego
Teva Investigational Site 10243, San Jose
Teva Investigational Site 10247, Miami Lakes
Teva Investigational Site 10239, Tallahassee
Teva Investigational Site 10234, Tampa
Teva Investigational Site 10253, Bangor
Teva Investigational Site 10257, Baltimore
Teva Investigational Site 10254, White Marsh
Teva Investigational Site 10235, Fall River
Teva Investigational Site 10236, North Dartmouth
Teva Investigational Site 10226, Minneapolis
Teva Investigational Site 10233, Minneapolis
Teva Investigational Site 10241, St Louis
Teva Investigational Site 10229, Bellevue
Teva Investigational Site 10227, Rochester
Teva Investigational Site 10244, Charlotte
Teva Investigational Site 10248, Cincinnati
Teva Investigational Site 10249, Oklahoma City
Teva Investigational Site 10232, Eugene
Teva Investigational Site 10259, Medford
Teva Investigational Site 10237, Portland
Teva Investigational Site 10240, Bethlehem
Teva Investigational Site 10246, Pittsburgh
Teva Investigational Site 10256, Pittsburgh
Teva Investigational Site 10251, Rock Hill
Teva Investigational Site 10228, Spartanburg
Teva Investigational Site 10258, San Antonio
Teva Investigational Site 10245, Seattle
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY